Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FGFR2
Variant V565I
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions FGFR2 V565I (corresponds to V564I in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V565I results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).
Associated Drug Resistance Y
Category Variants Paths

FGFR2 mutant FGFR2 act mut FGFR2 V565I

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_022970.4
gDNA chr10:g.121496705C>T
cDNA c.1693G>A
Protein p.V565I
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001144913.1 chr10:g.121496705C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
NM_022970 chr10:g.121496705C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
NM_022970.4 chr10:g.121496705C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
NM_022970.3 chr10:g.121496705C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121496705C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
NM_001144913 chr10:g.121496705C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
XM_024447890.1 chr10:g.121488077C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
XM_006717711 chr10:g.121488077C>T c.1693G>A p.V565I RefSeq GRCh38/hg38
XM_024447890.2 chr10:g.121488077C>T c.1693G>A p.V565I RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 V565I Advanced Solid Tumor resistant Dovitinib Preclinical Actionable In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597). 23908597
FGFR2 V565I Advanced Solid Tumor resistant Ponatinib Preclinical Actionable In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Iclusig (ponatinib) (PMID: 23908597). 23908597
FGFR2 V565I Advanced Solid Tumor resistant PD173074 Preclinical Actionable In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with PD173074 (PMID: 23908597). 23908597
FGFR2 V565I Advanced Solid Tumor predicted - sensitive TYRA-200 Preclinical - Cell culture Actionable In a preclinical study, TYRA-200 demonstrated activity in cells expressing FGFR2 V565I in culture (Eur J Cancer 2022 Vol 174, Supp 1:S16). detail...